Sun Pharma inches up on signing pact to develop nervous system drugs

Shares of Sun Pharma are up almost 1% at Rs 763 in a subdued market after the drug maker announced that it has entered into an agreement with Israel based Weizmann Institute of Science and Spain's Health Research Institute of Santiago de Compostela to develop products for treating neurological diseases like brain stroke and glioblastoma, a lethal brain cancer.

Scientists at Weizmann Institute have developed a recombinant enzyme currently undergoing animal studies for indications of brain stroke and glioblastoma.

Further studies of this enzyme will be conducted at the Health Research Institute of Santiago de Compostela in Spain. CLICK HERE FOR FULL STORY

The stock opened at Rs 759 and touched an intraday high of Rs 766 on the BSE. At 10:20 am, around 600,000 shares were traded on both the stock exchanges.

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel